Factors influencing the variation in GMS prescribing expenditure in Ireland by Conway Lenihan, Aisling et al.
Cork Institute of Technology 
SWORD - South West Open Research 
Deposit 
Articles Management & Enterprise 
2016-03-29 
Factors influencing the variation in GMS prescribing expenditure 
in Ireland 
Aisling Conway Lenihan 
S. Ahern 
J. Cronin 
N. Woods 
Follow this and additional works at: https://sword.cit.ie/dptmeart 
 Part of the Community Health and Preventive Medicine Commons, Economic Policy Commons, Health 
and Medical Administration Commons, Health Economics Commons, Health Policy Commons, Health 
Services Administration Commons, and the Health Services Research Commons 
RESEARCH Open Access
Factors influencing the variation in GMS
prescribing expenditure in Ireland
A. ConwayLenihan1*, S. Ahern2, S. Moore2, J. Cronin2 and N. Woods2
Abstract
Background: Pharmaceutical expenditure growth is a familiar feature in many Western health systems and is a
real concern for policymakers. A state funded General Medical Services (GMS) scheme in Ireland experienced an
increase in prescription expenditure of 414 % between 1998 and 2012. This paper seeks to explore the rationale
for this growth by investigating the composition (Anatomical Therapeutic Chemical (ATC) Group level 1 & 5) and
drivers of GMS drug expenditure in Ireland in 2012.
Methods: A cross-sectional study was carried out on the Health Service Executive-Primary Care Reimbursement
Service (HSE-PCRS) population prescribing database (n = 1,630,775). Three models were applied to test the
association between annual expenditure per claimant whilst controlling for age, sex, region, and the pharmacology of
the drugs as represented by the main ATC groups.
Results: The mean annual cost per claimant was €751 (median = €211; SD = €1323.10; range = €3.27–€298,670). Age,
sex, and regions were all significant contributory factors of expenditure, with gender having the greatest impact (β =
0.107). Those aged over 75 (β =1.195) were the greatest contributors to annual GMS prescribing costs. As regards
regions, the South has the greatest cost increasing impact. When the ATC groups were included the impact of gender
is diluted by the pharmacology of the products, with cardiovascular prescribing (ATC ‘C’) most influential (β =
1.229) and the explanatory power of the model increased from 40 % to 60 %.
Conclusion: Whilst policies aimed at cost containment (co-payment charges; generic substitution; reference
pricing; adjustments to GMS eligibility) can be used to curtail expenditure, health promotional programs and
educational interventions should be given equal emphasis. Also policies intended to affect physicians’ prescribing
behaviour include guidelines, information (about price and less expensive alternatives) and feedback, and the use
of budgetary restrictions could yield savings in Ireland and can be easily translated to the international context.
Background
Pharmaceutical expenditure is a considerable and growing
cost to health care systems in Western European Union
(EU) countries, including Ireland. Consequently, it is
important to identify the factors influencing this rise in
expenditure so as to ensure the sustainability of health
systems going forward. Information on pharmaceutical
expenditure trends is necessary to facilitate informed
decision making about efficient resource allocation,
optimum budget allocation, and future policy decisions.
Pharmaceutical expenditure growth is not a recent
phenomenon as it has been growing faster than Gross
Domestic Product (GDP) in all European countries since
the 1980s [1]. A systematic review of the factors influen-
cing pharmaceutical expenditure identified that drug
utilisation; drug therapies; price; and new drugs; are the
main drivers of pharmaceutical expenditure [2], and
population growth and aging have been found to be add-
itional factors in Ireland [3]. In 2012, Ireland spent 14 %
of total government expenditure on health which is
comparable with the EU average (EU 28 average). Irish
health spending accounted for 8.9 % of GDP, just above
the EU28 average of 8.7 % [4].
Approximately 14 % of public health expenditure in
Ireland was spent on pharmaceuticals in 2012 [5]. Irish
pharmaceutical expenditure per capita relative to other
Organisation for Economic Co-Operation and Develop-
ment (OECD) countries increased significantly from 20th
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highest of 27 countries in 2000 to 3rd highest of 25
countries in 2010 [6]. In 2012, the state accounted for
€2.6 billion (19 %) of overall health expenditure
(€13.71bn) in Ireland through its publicly funded Com-
munity Drug Schemes (CDS). There are eleven CDS
schemes. The General Medical Services (GMS) scheme
accounted for €1.28 billion, 50 % of community drug
expenditure, the High Tech Drugs scheme accounted
for 385 million (15 %) and the Drug Payments scheme
accounted for 126 million (5 %). This paper focuses on the
GMS scheme, the largest community drug scheme [7].
The most significant contributor to pharmaceutical
expenditure in Ireland is the GMS (medical card)
scheme. This is a community drug scheme, whereby
drugs, medicines and appliances supplied under the
Scheme are provided through retail pharmacies. All
GMS claims are processed and paid by the Primary
Care Reimbursement Service (PCRS). The scheme is
means tested and eligibility is based on income. Persons
who are affected by certain medical conditions are also
eligible for the scheme. Those who are unable without
undue hardship to arrange general practitioner medical
and surgical services for themselves and their depen-
dants are eligible to receive free general medical service
under the scheme and are issued with a medical card.
The scheme is financed by the state with a co-payment
from each eligible person introduced in 2010. Since
October 2010, each person on the scheme has in-
curred a €0.50 charge for every prescription item dis-
pensed. This was subsequently increased to €1.50 in
2013 and is currently €2.50 per prescription item up to
a maximum of €25 per family per month. Between July
2001 and December 2008, all persons over 70 were
granted a free medical card. Due to the economic crisis,
eligibility criteria were introduced on the 1st of January
2009 so that all persons ≥70 were means tested.
Since 2000 GMS expenditure on pharmaceuticals has
been rising rapidly, as illustrated in Fig. 1. The govern-
ment introduced cost containment measures during the
economic crisis to combat this trend such as co-
payment charges for claimants,1 adjustments to GMS
eligibility criteria, reference pricing and the promotion
of generic substitution [8]. Despite these measures,
Irish pharmaceutical spending per capita in 2012 was
the third highest amongst EU countries at €500, 40 %
above the EU average (€350) [4]. The total cost of GMS
prescriptions has increased from €249 million in 1998
to €1.24 billion in 2009 (400 % increase) as illustrated
in Fig. 1. GMS expenditure accounted for 9 % of the
overall health budget in 2012 [9].
The total cost of GMS prescriptions decreased in 2010
and 2011, due to government cut backs and the intro-
duction in cost containment measures, before increasing
again to €1.28 billion in 2012, at a time when GMS
coverage rates2 increased from 35 % of the population in
1998 to over 40 % in 2012. A study of projected GMS
costs for Ireland found that GMS expenditure could rise
to €2.5 billion by 2026 [10].
Between 1998 and 2012, between 67 % and 70 % of
total annual GMS expenditure has been accounted for
by four of the Anatomical Therapeutic Chemical (ATC)
groups; Nervous (N) system, Cardiovascular (C) system,
Alimentary Tract and Metabolism (A) system and Re-
spiratory (R) system (Annual (PCRS) Reports, 1998–
2012). In 2012, €872 million of total GMS expenditure
(€1288.82 million) was recorded across the four ATC
groups equating to 68 % of GMS expenditure [7]. Table 1
reports the findings of previous studies.
The objective of this research is to investigate the sig-
nificant drivers of GMS expenditure whilst controlling
for age, gender, regional disparities, and the main thera-
peutic use of the main active ingredient of medicinal
Fig. 1 Total Cost (€m) of GMS Prescriptions between 1998 and 2012
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products i.e., ATC groups. The main contribution of this
paper will identify the ATC groups by gender, age and
region generating the highest level of cost. It will identify
the ATC Level 5 i.e., specific drug within the ATC group
that are generating the highest cost. We make recom-
mendations on what policies that can be introduced to
reduce cost and generate savings. These policies that will
reduce cost can be translated internationally and would
yield savings in the international context.
Methods
Study design and data
A cross-sectional study was carried out on the Irish
Health Service Executive (HSE)-PCRS pharmacy claims
database for the year 2012 (n = 1.63 million claimants).
Each GMS claimant is identified by a unique dispense
number. There are approximately 60 million observations
in the database and the data was aggregated to create one
observation per claimant. There are 40 variables in the
database, of which seven are included in this research.
These include demographic information (age, sex, region),
cost data (ingredient cost, Value Added Tax (VAT), dispens-
ing fees) and ATC group. For the purpose of this analysis,
total annual cost is the sum of ingredient cost, VATand dis-
pensing fees for 2012. The pharmacology is coded using
the World Health Organisation (WHO) ATC classification
system3 [11]. The analysis of the pharmacology is under-
taken at the 1st level of the ATC classification system.
Modelling health and drug expenditure varies inter-
nationally [2]. A number of studies have used Ordinary
Least Squares (OLS) to model the variation in drug and
health costs [12–18]. Following a review of the literature
and expert opinion, the OLS regression model was
deemed the most appropriate model to use.
Table 1 Previous Studies
Country Author Findings
British Colombia (2006) Morgan [24] A population study on drug expenditure in 1996 and 2002 found 75 % of total drug costs
were accounted for by 5 ATC groups in descending order of expenditure, ‘C’, ‘N’, ‘A’, ‘G’
(Genito Urinary System & Sex Hormones) and ‘J’ (Anti-infectives for Systemic Use).
Sweden (1998) Gerdtham et al. [34] This study identified ATC group ‘N’ contributed the most to drug expenditure.
Sweden (2004) Gerdtham & Lundin
[35]
This study identified ATC groups ‘N’, ‘C’ ‘and ‘A’ contributed the most to drug expenditure.
Sweden (2003) Klarin et al. [36] A study carried out on an elderly population (84+) found ‘C’, ‘N’ and ‘A’ were the most
commonly prescribed drugs.
Spain (2011) Vivas et al. [13] This study reported the cost of drugs used to treat hyperlipidemia (from ATC ‘C’), respiratory
illnesses, asthma (from ATC ‘R’) and diabetes (from ATC ‘A’) represents 37 % of total
pharmaceutical expenditure on chronic conditions in Valencia.
Ireland (2006) Naughton et al. [21] A study based on an elderly Irish population (≥70 years) found that Cardiovascular Disease (CVD)
is the most prevalent condition across all regions using a 2006 PCRS pharmacy database.
Various Studies [3, 10, 20, 26, 30, 37] A number of studies have identified age as a factor influencing pharmaceutical spending.
United States (1997) Mueller et al. [30] A study in the United States found the elderly (65+) accounted for 34 % of total pharmaceutical
expenditure, children (≤17) accounted for 9 %, and those aged (18–64) accounted for the
remaining 57 %. Of total drug expenditure, 41 % was spent on cardiovascular and renal drugs
and 14 % on respiratory tract drugs.
3 European Countries
(2008)
Sturkenboom et al. [20] This study found that respiratory drugs were the most prescribed drugs and cardiovascular
drugs were the least prescribed drugs for children (≤18).
Spain (2008) Fernandez et al. [26] A study in Catalonia, investigated how age influenced drug utilisation and found drug use
was highest among infants (0–4) and those aged 55 and older.
Ireland (2015) Conway et al. [10] A recent study identified children (≤11) and the over 65 s as the two key drivers of future
GMS costs in Ireland.
Various Studies [2, 13, 23, 37] Several studies have reported that females are more likely to utilise drugs than males.
United States (2000) Steinberg et al. [37] Males aged 65 and over were 50 % more likely not to be prescribed any drugs.
Sweden (2013) Loikas et al. [23] This study examined gender differences in drug prescribing and found 59 % of men and 76 %
of women were dispensed at least one drug. Females were found to be prescribed more
nervous drugs and males more lipid lowering (cardiovascular) drugs.
Various Studies [12, 14, 15] Geographical location is also considered in international studies as a predictor of pharmaceutical
expenditure.
United States (2003) Wrobel et al. [12] A Medicare study examined the predictability of drug expenditure and found demographic
variables (age, sex, disability & geographic location), explained only 5 % of the variation in
drug expenditure. The inclusion of health status measures improved the explanatory
power considerably.
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Empirical analysis
Three models were developed to investigate the associ-
ation between the total annual GMS cost per claimant
and the independent variables. The cost data is positively
skewed (skewness = 16.140) and a log transformation
was applied to normalise the data. This approach has
been previously used [17, 19]. In the first model we esti-
mate the impact on the log of annual total cost per
claimant using OLS regression whilst controlling for age,
sex, and the 4 HSE regions (Dublin Mid-Leinster (ML),
Dublin North East (NE), South and West). The square
and cube of age were considered as age has a non-linear
relationship with the log of total cost. The inclusion of
these two variables does not add to the explanatory
power of the model and were excluded.
In the first model we estimate the impact of age, sex
and region on the log of total cost.
LogTC ¼ β0 þ β1X1 þ β2X2 þ β3X3 þ…þ β5X5 þ ε
where β0 is the constant, X1 = age, X2 = female, X3 =
Dublin ML, X4 =West and X5 = South, (Reference cat-
egory = Dublin NE, Male).
In the second model in addition to the demographic
variables, we estimate the impact of pharmacology on
the log of total cost by including the main ATC groups.
LogTC ¼ β0 þ β1X1 þ β2X2 þ β3X3 þ…þ β8X8 þ ε
where X1 = age, X2 = female, X3 = Dublin ML, X4 =West,
X5 = South, X6 = ‘A’ ATC group, X7 = ‘C’ ATC group and
X8 = ‘N’ ATC group (Reference category = Dublin NE, ‘R’
ATC, Male).
In the third model in addition to the demographic and
pharmacological variables, we estimate the model using 11
age categories, to ascertain the impact of age categories
on cost.
LogTC ¼ β0 þ β1X1 þ β2X2 þ β3X3 þ…þ β17X17 þ ε
where X1 = female, X2 =Dublin ML, X3 =West, X4 = South,
X5 = ‘A’ ATC group, X6 = ‘C’ ATC group and X7 = ‘N’ ATC
group, plus 10 dummy variables for age cohort (X8-X17).
(Reference category Age = 12–15, Dublin NE, ‘R’ ATC
group, Male)
The models were estimated by OLS regression. Each
model was tested for normality, homoscedasticity and
linearity. The Variance Inflation Factor (VIF) and toler-
ance factors were obtained to test for multicollinearity.
All statistical tests were two-sided at the 5 % significance
level. Aggregation by GMS claimant was carried out in
R Studio version 2.15.3. Statistical Analysis was per-
formed using SPSS 22.
Results
Statistical analysis
The mean annual cost per claimant was €751
(median = €211; SD = €1323.10; range = €3.27–€298,670).
As regards age, 14 % were 75 or over, with 4 % between
12 and 15. Over 55 % of claimants were female. In terms
of their regional distribution, 28 % were located in the
Southern region, 26 % in both Western and Dublin ML,
and 20 % in Dublin NE. With reference to pharmacol-
ogy, 52 % were prescribed an ‘N’ prescription item, 45 %
an ‘A’ item, 39 % an ‘R’ item and 36 % a ‘C’ prescription
item. In 2012, 19 % of claimants were prescribed items
from ATC groups other than ‘A’ ‘C’ ‘N’ or ‘R’accounting
for almost €19 million of the total annual cost.
The following descriptive analysis is based on claim-
ants (n = 1,313,825) who were prescribed an ‘N’, ‘C’, ‘A’ or
‘R’ prescription item. Table 2 presents GMS expenditure
(€) by claimants categorised by age category and ATC
group.
Table 2 shows that 51 % of claimants in the under 5’s
were prescribed ‘R’ prescription items, whereas just 2 %
were prescribed ‘C’ items. Of those aged 25–34, 42 %
were prescribed ‘N’ items, whereas 8 % were prescribed
‘C’ items. For those aged 75 and over, 30 % were pre-
scribed ‘C’ items with 16 % prescribed ‘R’ items. Analysis
of expenditure by ATC level 2 identified that respiratory
drugs, principally for the treatment of obstructive airway
diseases such as asthma, recorded the highest proportion
of claimants and total expenditure for those up to the
age of 15. Nervous system drugs predominantly for the
treatment of depression, anxiety, psychotic conditions,
and epilepsy, recorded the highest proportion and ex-
penditure for those between 16 and 64 years. Cardiovas-
cular drugs, particularly statins, recorded the highest
proportion and expenditure for those over 65.
Of overall expenditure in 2012, 55 % was due to pre-
scribing claims by females with the proportion of ner-
vous system items (31 %) the major component of this
expenditure (Table 3). There was a higher proportion of
male claimants up to age 15 in ATC groups ‘R’, and a
higher proportion up to age 11 for ATC ‘N’.
Table 4 shows that the South region contributed over
€240 m (29 %) to the overall prescribing expenditure in
2012 and was the most expensive region across the four
ATC groups. Drugs for the treatment of the nervous sys-
tem records the highest proportion across the four re-
gions. Dublin ML and Dublin NE record the highest
percentage of claimants for the nervous and respiratory
system and the West and South record the highest per-
centage of cardiovascular claimants. Of the 427,257
claimants in Dublin ML, incorporating Dublin City, 31 %
were prescribed nervous system items, whereas just 20 %
were prescribed cardiovascular items, largely explained by
a relatively younger population in Dublin ML.
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Results of empirical analysis
In Table 5 the results of the empirical analysis are pre-
sented based on estimates from three models. Model 1
shows that whilst age, sex and regions are all significant
drivers of expenditure, gender (female) had the greatest
impact (β = 0.107). Additional claimants in the South re-
gion will have greatest cost increasing impact. However,
when the ATC groups were included in model 2, the
impact of gender was diluted, with cardiovascular prescrib-
ing most influential (β = 1.229) and the explanatory power
of the model increases from 40 % to 60 %. The inclusion of
age dummies in model 3 expectedly shows those aged over
75 (β =1.195) added most to GMS costs. Multicollinearity
was not violated as VIF values did not exceed ten, Toler-
ance values were greater than 0.1. Mahalanobis and Cook’s
distances tests were carried out to check for outliers. For
the residuals output, the max value for Cook’s distances did
not exceed 1 and the max value for Mahalanobis distances
did not exceed the critical χ2 value.
Discussion
Our investigation identified significant factors [age, sex,
region and pharmacology of the drugs] influencing mean
GMS expenditure per claimant in Ireland for 2012. This
research also identified the drugs (ATC level 5) that
incur the highest level of expenditure by age group. The
impact of age on expenditure followed a similar pattern
as observed in the literature, highest expenditure on re-
spiratory drugs for those under 15, highest on nervous
system drugs for those between 16 and 64, and highest
on cardiovascular drugs for those aged 65 and over. A
recent study reported that children (0–11) and the elderly
(70+) will be a key driver of future drug costs in Ireland
[3]. A three country study (UK, Italy & Netherlands)
found the respiratory system to be one of 3 ATC groups
with the highest prevalent rates in children [20]. A study
in Ireland found that cardiovascular disease is the most
prevalent condition in an elderly population aged 70 and
over, indicating the trend has continued between 2004 and
2012 [21]. However, a study in Denmark found treatment
intensity and prevalence contributed to drug expenditure
costs rather than population aging [22].
In terms of gender differences in prescribing, females
account for more than half of GMS claimants in 2012,
and were found to be more expensive across the 4 ATC
groups with the highest expenditure for nervous system
drugs and the smallest for cardiovascular. A study on a
Swedish population in 2010 concurs with our findings,
which found a greater proportion of men were prescribed
cardiovascular drugs whilst a greater proportion of women
Table 3 Percentage of GMS Claimants & GMS Expenditure (€m) by ATC group and Sex (2012)
Sex N C A R Total (€m) Total GMS
% (€m) % (€m) % (€m) % (€m) N,C,A,R Cost (€m)
Females 31 178.02 20 125.31 27 96.23 22 62.80 462.37 687.12
Males 29 124.82 22 113.75 25 76.53 23 52.54 367.64 537.74
% of Total 36 302.85 29 239.06 21 172.76 14 115.34 830.01 1224.86
N Nervous System, C Cardiovascular System, A Alimentary Tract & Metabolism, R Respiratory System
The most expensive group (females) is highlighted in bold The underlined data in Table 3 shows the highest prescribing frequency for females (N,A) and males (C,R)
Table 2 Percentage of GMS Claimants & Expenditure Euro million (€m) by ATC group and Age Category (2012)
Age Cohort N C A R Total (€m) Total GMS
% (€m) % (€m) % (€m) % (€m) N,C,A,R Cost (€m)
<5 16 0.57 2 0.35 32 0.88 51 2.01 3.81 12.35
5–11 10 1.78 2 0.29 24 1.13 64 4.33 7.53 9.46
12–15 28 1.87 2 0.11 20 0.97 50 2.15 5.10 4.76
16–24 40 9.32 5 0.52 25 3.44 31 3.91 17.20 17.12
25–34 42 27.11 8 1.80 26 7.29 24 5.32 41.52 23.69
35–44 39 39.83 13 6.83 26 12.39 22 7.62 66.68 28.19
45–54 34 46.03 21 19.31 26 19.79 19 11.32 96.45 35.65
55–64 29 46.33 27 40.68 26 29.53 18 18.56 135.11 55.41
65–69 26 23.58 30 31.59 26 19.27 17 13.06 87.49 37.30
70–74 26 27.10 32 43.61 26 23.28 16 15.22 109.21 51.13
>75 27 79.32 30 93.97 27 54.78 16 31.85 259.92 119.79
% of Total 36 302.85 29 239.06 21 172.76 14 115.34 830.01 394.86
N Nervous System, C Cardiovascular System, A Alimentary Tract & Metabolism, R Respiratory System
The most expensive age category by ATC group is highlighted in bold
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were prescribed nervous system drugs [23]. A higher
female per capita expenditure was reported for nervous
and alimentary tract and metabolism drugs in a study
in British Colombia with males highest expenditure on
cardiovascular drugs [24]. Coronary artery disease was
more common in men over 60 than females in Sweden
[25]. We reported that males under 11 years were pre-
scribed more prescription items than female which
concurs with higher drug usage in adolescent males
compared to females in both Catalonia and Sweden
[23, 26].
In terms of regional variation, the South region recorded
the highest prescribing expenditure and Dublin NE the
lowest. Dublin ML recorded the highest proportion of ner-
vous prescription items and Dublin ML recorded the low-
est for cardiovascular items. Two Irish studies [27, 28]
found variations for Ischaemic heart disease and diabetes
respectively, in prescribing by old health board regions.4
They found high prescribing rates in the Midlands and
Eastern regions and low prescribing rates in the Western
and North-Western regions. Furthermore, an Irish study
found variation in projected drug costs by old health
board regions where the Midlands region was the most
expensive region which is now part of the Dublin ML re-
gion [3]. Research on prescribing in Canada reported that
individual characteristics and living environment affect
prescription use and may explain regional variations in
prescription use. For example, area level measures of
population health and socioeconomic status affected the
likelihood of prescription use [29].
In examining the factors driving expenditure, we also
investigated the most costly prescription items. Drugs
for the treatment of the nervous system were the great-
est contributor to prescribing expenditure in 2012. An
important finding of this paper identified the most
Table 4 Percentage of GMS Claimants and Expenditure (€m) by
ATC group and HSE Region (2012)
Region N C A R Total
% (€m) % (€m) % (€m) % (€m) (€m)
Dublin ML 31 79.85 20 61.18 26 46.26 23 31.39 218.67
Dublin NE 31 56.05 21 46.45 26 33.05 23 22.46 158.01
West 30 78.91 22 60.38 26 44.25 22 29.36 212.91
South 30 88.04 22 71.05 26 49.20 22 32.13 240.42
% of Total 36 302.85 29 239.06 21 172.76 14 115.34 830.01
N Nervous System, C Cardiovascular System, A Alimentary Tract & Metabolism,
R Respiratory System
The most expensive group (South) is highlighted in bold
Table 5 Estimates from Multivariate Regression Models 1–3
Variables Model 1 Model 2 Model 3
β C1 95 % t-stat β C1 95 % t-stat β CI 95 % t-stat
Constant 3.339 3.288 3.324
Sex (F) 0.107 (0.103;0.112) a47.84 0.018 (0.015;0.022) a10.07 0.025 (0.021;0.029) a13.66
Age 0.044 (0.044;0.045) a1043.44 0.015 (0.015;0.015) a306.74
Dublin ML 0.026 (0.019;0.032) a7.76 −0.003 (−0.008;0.002) a-1.16 −0.003 (−0.009;0.002) −1.20
West −0.017 (−0.024;-0.011) a-5.16 0.008 (0.003;0.014) a3.07 0.009 (0.003;0.014) a3.21
South 0.056 (0.050;0.063) a17.08 0.038 (0.033;0.043) a14.21 0.037 (0.032;0.043) a14.00
Alimentary 0.911 (0.907;0.915) a440.64 0.903 (0.899;0.907) a436.51
Cardiovascular 1.229 (1.224;1.234) a478.42 1.193 (1.188;1.198) a452.28
Nervous 0.927 (0.923;0.931) a456.61 0.947 (0.943;0.951) a454.63
<5 0.117 (0.106;0.128) a21.57
5–11 0.103 (0.092;0.113) a19.23
16–24 0.237 (0.227;0.247) a45.55
25–34 0.370 (0.360;0.381) a72.09
35–44 0.475 (0.465;0.485) a92.06
45–54 0.706 (0.696;0.717) a131.29
55–64 0.957 (0.946;0.968) a172.64
65–69 1.071 (1.059;1.083) a173.49
70–74 1.126 (1.114;1.137) a189.07
>75 1.195 (1.184;1.206) a215.44
Adjusted R2 0.402 0.604 0.605
aStatistically significant at 5 % level
The dependent variable was the logarithim of annual total GMS cost (€) per claimant
Baseline - Males, age category 12–15, Dublin NE and ATC ‘R’. (least cost variables)
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expensive drugs in each ATC group by age cohort. Escita-
lopram which treats depression and anxiety accounts for
the highest expenditure (€0.74 m; 1 % of ‘N’) for 16 to
24 year olds and Olanzapine which treats psychotic condi-
tions such as schizophrenia and bipolar disorder accounts
for the highest expenditure (€2.48 m; 1 % of ‘N’) for 25 to
34 year olds. Expenditure on Pregabalin (€16.95 m; 10 %
of ‘N’) in 35 to 64 year olds for the treatment of conditions
such as epilepsy contributed to 10 % of prescription items
for ATC ‘N’.
Respiratory drugs was the main contributor to GMS
drug expenditures in children up to the age of 15 and
this is corroborated by the literature [26, 30]. With an
increasing incidence of asthma in developed countries,
it’s not surprising that drugs for the treatment of obstruct-
ive airway diseases, such as Montelukast (€2.4 m; 29 % of
‘R’), and inhalers such as Salbutamol and Beclometasone
are amongst the greatest contributors to expenditure for
ATC group ‘R’. A childhood study in Ireland reported that
cigarette smoke, atopy, and the presence of certain furry
pets, are determinants of respiratory symptoms in chil-
dren [31].
Cardiovascular prescription expenditure in 2012 was
mainly influenced by the prescribing of statins (Atorva-
statin, Rosuvastatin, Pravastatin, Simvastatin and Fluvasta-
tin) [7]. Atorvastatin has since come off patent, which
should help reduce costs associated with high cholesterol.
The greater promotion of generic prescribing for these
drugs would lead to cost savings.
Expenditure on Esomeprazole (€31.25 m; 18 % of ‘A’),
a Proton Pump Inhibitor (PPI) which is used to treat
certain stomach and oesophagus conditions, such as ul-
cers and acid reflux, contribted 18 % of expenditure on
alimentary tract and metabolism items. In 2012, PPI’s
were the second most expensive group of medicines
after statins [7]. An Australian study investigated the
utilisation of PPI’s and found Esomeprazole to be the
second most prescribed PPI and the second most expen-
sive group of medicines after statins [32]. An Irish study
on the GMS scheme investigated whether cost savings
could be made by changes in prescribing practice. They
found if Esomeprazole was substituted with a less expen-
sive alternative, it would create savings of approximately
€3.3 million [33].
Our analysis highlighted a significant difference between
the mean expenditure per claimant and the median. This
is explained by high cost users of prescription items in our
population. The characteristics of high cost users need
further investigation. An important strength of this study
is that it provides a population based overview of drug
utilisation and expenditure across four ATC groups.
This study is subject to certain limitations. The HSE-
PCRS has pre-defined age cohorts, therefore making it
difficult to re-construct age cohorts to make comparisons.
The age band widths are not equal across the 11 HSE age
cohorts. The HSE-PCRS database lacks a unique health
identifier, which precludes the link between pharmacy data
and other health data such as mortality data. The analysis
is limited to the HSE-PCRS database which relates to pub-
lic patients only.
Conclusion
All European countries have common concerns about
growing drug expenditures. The growing proportion of
the elderly, the increase in the incidence and duration of
chronic diseases, the continuing development of health
technologies, and the increase in health expectation of
society, are common factors across all countries. Our re-
search indicates that growth in the proportion of elderly
claimants and associated levels of cardiovascular pre-
scribing, particularly for statins, will present difficulties
for Ireland in terms of cost containment. The primary
prevention of CVD is dependent on the effective reduction
of the major risk factors, particularly tobacco control and
a healthier diet. Policies aimed at population-wide CVD
prevention, such as legislating for smoke-free public
spaces, banning dietary transfats, or halving daily dietary
salt intake are generally effective and cost saving. Based on
prevalence rates and related prescribing costs of asthma
among children up to the age of 15, it is imperative that
public health resources and educational efforts are tar-
geted to improve asthma control and reduce the disease
burden on both the healthcare system and society. Ex-
penditure on nervous system drugs in Ireland are high-
est for those aged between 16 and 64, in particular,
drugs for the treatment of anxiety and depression. The
treatment of anxiety and depression is vitally important
with the growth in suicidal related deaths in Ireland.
Whilst pharmacological treatments are often necessary,
changes in prescribing practice combined with psycho-
logical therapies, cognitive methods, and self-help strat-
egies, can yield cost savings. Since October 2013, a
generic substitute for Esomeprazole is now available
which could generate substantial savings in alimentary
tract prescribing. Whilst policies aimed at cost containment
such as co-payment charges, generic substitution, reference
pricing, and adjustments to GMS eligibility can be used to
curtail expenditure, health promotional programs and
educational interventions should be given equal emphasis.
Furthermore, policies intended to affect physicians’
prescribing behaviour include guidelines, information
(about price and less expensive alternatives) and feedback,
and the use of budgetary restrictions could also yield
significant savings.
Endnotes
1A claimant is a person who is eligible for a GMS card
and makes a claim.
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2GMS coverage refers to the proportion of the population
who have a medical card.
3In the Anatomical Therapeutic Chemical (ATC) clas-
sification system, the active substances are divided into
different groups according to the organ or system on
which they act and their therapeutic, pharmacological
and chemical properties. Drugs are classified in groups
at five different levels. The drugs are divided into four-
teen main groups (1st level), with pharmacological/thera-
peutic subgroups (2nd level).
4The 8 Health Service Executive (HSE) regions were
restructured to 4 Regions (Dublin ML; Dublin NE; South;
West) in 2010.
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